|
Novel Assay Technologies Highlighted at Molecular Pharmacology
ACADIA Pharmaceuticals Inc has reported on the development of assay technologies for a major class of drug targets, tyrosine kinase linked receptors, RTKs. This important gene family has been demonstrated to play a significant role in the development of many disease states, including CNS disorders and cancer.
In a poster presentation at the Molecular Pharmacology Gordon Conference, ACADIA highlighted a novel application of BRET technology used to measure the interaction of RTKs with several signaling proteins. This assay technology allowed ACADIA scientists to define the biology of mutant forms of the epidermal growth factor receptor that have been associated with lung cancer. ACADIA scientists have found that these mutations induce constitutive signaling through several proteins. Iressa and Tarceva, two drugs used to treat cancer, block this constitutive signaling with potencies that are dependent on the signaling protein and the specific mutation.
Acadia Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. Using its proprietary drug discovery platform, Acadia has discovered all of the drug candidates in its product pipeline. Acadia's corporate headquarters and biology research facilities are located in San Diego, California and its chemistry research facilities are located near Copenhagen, Denmark.
For further information please contact:
Bo-Ragner Tolf,
Vice President
Tel: +45 43 29 30 00
Email: btolf@acadia-pharm.com
|
